Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes

被引:21
作者
Gutniak, MK
Svartberg, J
Hellström, PM
Holst, JJ
Adner, N
Ahrén, B
机构
[1] Univ Lund, BMC, Dept Med, SE-22184 Lund, Sweden
[2] Soder Sjukhuset, Dept Med, S-10064 Stockholm, Sweden
[3] Univ Tromso Hosp, Dept Med, N-9038 Tromso, Norway
[4] Karolinska Hosp, Dept Gastroenterol & Hepatol, S-10401 Stockholm, Sweden
[5] Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark
关键词
gastric emptying; GLP-1; standard meal; type; 2; diabetes;
D O I
10.1046/j.1365-2796.2001.00862.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective, To establish the antidiabetogenic effect of glucagon-like peptide-1 (GLP-1) when differently administered relative to meal intake in subjects with type 2 diabetes, Design, The study was a placebo-controlled comparison with random assignment to treatment sequence. A 3-h stepwise infusion of GLP-1 (17 nmol) was started either at the onset of a standard meal (550 kCal) (A) or at 30 min (B) or 60 min (C) after the start of the meal. Setting, The study was conducted at a university hospital. Subjects, Eight patients with type 2 diabetes (four women and four men), age 62 +/- 3.9 years (range 47-74 years), weight 79.8 +/- 5.4 kg (range 62-104 kg), BMI 26.2 +/- 1.3 kg m(-2) (range 21-31 kg m(-2)), diabetes duration 10.5 +/- 2.0 years (range 3-19 years) and HbA1c levels 6.1 +/- 0.3% (range 4.7-7.7%) participated in the study. All patients were treated with oral sulphonylureas. Results. Glucagon-like peptide-1 significantly lowered postprandial glycaemia by a similar degree in all three situations versus the control meal(P < 0.05). Postprandial insulin levels were not different in the four experimental series, whereas the postprandial glucagon levels were significantly lowered by GLP-1 in (A) and (B) (P < 0.03) but not in (C). Gastric emptying, as determined by the paracetamol test, was retarded by GLP-1 only in (A) (P < 0.01), but not affected in (B) or (C). Conclusions. GLP-1 reduced postprandial hyperglycaemia in subjects with type 2 diabetes regardless of administration at the onset of meal intake or at 30 or 60 min after start of meal intake, although the mechanism of the antidiabetogenic action of GLP-1 depended on administration versus meal intake. Thus, when administered at the start of a meal, GLP-1 was antidiabetogenic mainly through retarding gastric emptying, whereas when given at 30 or 60 min after meal ingestion, changes in islet hormone secretion seem to be predominant.
引用
收藏
页码:81 / 87
页数:7
相关论文
共 26 条
[1]  
ARNQVIST H, 1987, CLIN CHEM, V33, P93
[2]   Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients [J].
Creutzfeldt, WOC ;
Orskov, C ;
Kleine, N ;
Holst, JJ ;
Willms, B ;
Nauck, MA .
DIABETES CARE, 1996, 19 (06) :580-586
[3]   Glucagon-like peptide-1(7-36)-amide confers glucose sensitivity to previously glucose-incompetent beta-cells in diabetic rats: in vivo and in vitro studies [J].
Dachicourt, N ;
Serradas, P ;
Bailbe, D ;
Kergoat, M ;
Doare, L ;
Portha, B .
JOURNAL OF ENDOCRINOLOGY, 1997, 155 (02) :369-376
[4]   Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans [J].
Flint, A ;
Raben, A ;
Astrup, A ;
Holst, JJ .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (03) :515-520
[5]   ANTIDIABETOGENIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE IN NORMAL SUBJECTS AND PATIENTS WITH DIABETES-MELLITUS [J].
GUTNIAK, M ;
ORSKOV, C ;
HOLST, JJ ;
AHREN, B ;
EFENDIC, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (20) :1316-1322
[6]   Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas [J].
Gutniak, MK ;
Guenifi, A ;
Berggren, LJ ;
Holst, JJ ;
Hellstrom, PM ;
Efendic, S .
DIABETES CARE, 1996, 19 (08) :857-863
[7]   SUBCUTANEOUS INJECTION OF THE INCRETIN HORMONE GLUCAGON-LIKE PEPTIDE-1 ABOLISHES POSTPRANDIAL GLYCEMIA IN NIDDM [J].
GUTNIAK, MK ;
LINDE, B ;
HOLST, JJ ;
EFENDIC, S .
DIABETES CARE, 1994, 17 (09) :1039-1044
[8]   Potential therapeutic level of glucagon-like peptide I achieved in humans by a buccal tablet [J].
Gutniak, MK ;
Larsson, H ;
Heiber, SJ ;
Juneskans, OT ;
Holst, JJ ;
Ahren, B .
DIABETES CARE, 1996, 19 (08) :843-848
[9]   Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2 [J].
Gutzwiller, JP ;
Drewe, J ;
Göke, B ;
Schmidt, H ;
Rohrer, B ;
Lareida, J ;
Beglinger, C .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1999, 276 (05) :R1541-R1544
[10]   TRUNCATED GLUCAGONLIKE PEPTIDE-I, AN INSULIN-RELEASING HORMONE FROM THE DISTAL GUT [J].
HOLST, JJ ;
ORSKOV, C ;
NIELSEN, OV ;
SCHWARTZ, TW .
FEBS LETTERS, 1987, 211 (02) :169-174